Proliferation of vascular smooth muscle cells (VSMCs) is under the control of cell cycle regulator activity, which is induced by several growth factors. Recent attention has been drawn to treatments that target cell cycle regulators to prevent the proliferation of VSMCs after coronary angioplasty. However, histopathological evaluation of cell cycle regulator expression after human coronary stenting has not been sufficient.
divide in response to mitogens; the cells exit the G1 phase and enter the S phase. 4, 5) G1 phase is the rate-limiting period in the cell cycle. Once cells pass the restriction point in late G1 phase, no other mitogenic growth factors are required for cells to accomplish complete division. 6) Cell cycle transition is controlled by regulatory proteins including the cyclin and cyclin-dependent kinase (Cdk) complexes. 7) Cyclins become active when combined with Cdks. D-type cyclins play a crucial role in G1-S transition. 8) Cdk4 is one of the major catalytic partners of cyclin D. Cyclin D/Cdk4 complex activity is inhibited by Cdk inhibitors (CdkIs) such as p21, p27, and p16. 9) Growth factors are potent regulators of cellular function. They are bound to cell surface receptors, and through signal transduction pathways, they ultimately induce transcription of the genes for cyclins and other cell cycle regulators. 10) Among the growth factors, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (b-FGF) are known to strongly stimulate VSMC proliferation and migration. 4, 11) Histopathological investigation of human coronary stenting has already been reported. 2, 3) However, we have found no report discussing the expression of cell cycle regulators in human coronary arteries after stenting. Thus, we examined human coronary arteries histologically and immunohistochemically after stenting, with particular focus on the expression of cell cycle regulators and growth factors.
METHODS

Study patients:
We studied 31 stented coronary arteries obtained at autopsy from 23 patients. Patient and stent profiles are detailed in Tables I and II . Statistical analyses were performed using one-way ANOVA or χ 2 analysis.
Twenty-four of the 31 stents were placed as primary therapy for acute myocardial infarction, angina pectoris, or old myocardial infarction in lesions with greater than 75% stenosis. The 7 remaining stents were used as bail-out stenting (stents 1, 2, 5, 15, 17, 18, 24) for treatment of severe coronary dissection after balloon angioplasty. All stenting was performed with adjunctive PTCA, and all patients were treated with ticlopidine (200 mg per day) and aspirin (81 or 162 mg per day) immediately after stenting. Histological and immunohistochemical analysis: Coronary arteries were carefully dissected from autopsied hearts after fixation in 10% buffered formalin. The stent-containing tissues were cut transversely with fine scissors into 3-mm sections. After the tissue samples were embedded in paraffin, stent wires were care-Vol 45 No 1 fully removed with fine forceps so as not to destroy surrounding tissues. Each section was further cut into 8-µm-thick sections, and any residual wires were removed from each section. Sections were stained with Azan-Mallory, Elastica van Gieson, and phosphotungstic acid hematoxylin (PTAH) stains.
For immunohistochemical analysis, the following primary antibodies were used: mouse anti-human cyclin D1 monoclonal antibody, 1:100 dilution (No. MD-17-3, MBL); mouse anti-human p16 monoclonal antibody, 1:200 dilution (No. 1661, Santa Cruz Biotechnology); mouse anti-human p21 monoclonal antibody, 1:50 dilution (No. 15091A, PharMingen); mouse anti-human p27 monoclonal antibody, 1:100 dilution (No. M7203, DAKO); rabbit anti-human PDGF-A polyclonal antibody, 1:200 dilution (No. 128, Santa Cruz Biotechnology); and rabbit anti-human FGF-2 (b-FGF) polyclonal antibody, 1:200 dilution (No. 79, Santa Cruz Biotechnology). To detect cell proliferation, immunostaining using monoclonal mouse antiproliferating cell nuclear antigen (PCNA), 1:50 dilution (No. M 0879, DAKO) was carried out. Moreover, to detect VSMCs, mouse antihuman α-smooth muscle actin monoclonal antibody (α-SMA; No. M0815, DAKO) and rabbit anti-human c-Fms/CSF-1R (macrophage colony stimulation factor receptor: MCSF-R; No. 692, Santa Cruz Biotechnology) polyclonal antibody were used. Furthermore, we performed immunohistochemical staining with mouse anti-human macrophage monoclonal antibody (CD68; No. M0814, DAKO) to distinguish macrophages from among the MCSF-R-positive cells. Sections were incubated with the primary antibodies for 1 hour at room temperature after being autoclaved (15 psi, 121°C, 20 minutes) in 10 mM of citrate buffer for antigen activation. The streptavidin-biotin horseradish peroxidase method was used to detect antigens. 3,3'-Diaminobenzidine tetrahydrochloride was used to visualize horseradish peroxidase activity and hematoxylin was used for nuclear staining. For each tissue, one section was incubated with purified mouse or rabbit IgGs instead of primary antibodies as negative controls. 15  16  14  17  18  15  19  19  20  20  21  21  22  23   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31   0  0  0  1  2  4  7  9  9  15  19  22  31  35  40  45  59  59  60  60  67  109  111  150  150  160  160  166  166  190  235   79   86  73  81  62  79  64  71  75  89  80   78  55  75  62   91   53  71   76   77   86   62  82   AMI   AMI  AMI  AMI  AMI  AMI  AMI  AMI  AMI  AMI  AMI   AMI  AMID  Angina  AMI   Angina   AMI  AMI   AMI   OMI   AMI   OMI  OMI   GR-II  GR-II  Terumo  ML  PS  ML  Wiktor  S670  ML  ML  PS  GR-II  Wiktor  PS  GR-II  ML  GFX  NIR  ML  ML  NIR  GFX  NIR  S670  ML  GFX  ML  GFX  GR-II  Cordis  GR-II   LAD  LAD  LCX  RCA  RCA  RCA  LAD  LAD  RCA  RCA  LAD  LCX  RCA  LAD  LAD  LAD  LAD  LAD  LAD  RCA  LAD  LAD  RCA  LAD  LAD  RCA  LAD  LAD  LAD Quantitative analysis of each immunostain was performed by manual counts. The ratio of positive stained cells to all neointimal cells was calculated in five randomly chosen high-power (x 400) fields. Results of quantitative analysis are reported as a percentage (mean ± SD) and are divided into three stages according to time from stent implantation to death (0-14 days, 15-60 days, and 60 + days). One-way ANOVA was used for statistical analysis.
RESULTS
Fifteen of the 23 patients died from cardiac-related causes and 8 patients died from noncardiac causes (Table I) . Patients dying from cardiac causes had shorter intervals between stenting and death than the patients dying from noncardiac causes. Expression of MCSF-R and α-SMA: According to histological observation, the first vascular reaction to stent implantation was thrombus formation around stent struts ( Figure 1A ).
In the early stage after stenting, MCSF-R-positive cells were expressed in the thrombi ( Figure 1B) . Some MCSF-R-positive cells were recognized as macrophages; the other cells appeared to be redifferentiated VSMCs ( Figure 1B PCNA expression in neointima is shown in Figure 1E and F. Forty-five days after stenting, PCNA positive cells were observed in neointima ( Figure 1E ). The expression of PCNA was reduced 150 days after stenting ( Figure 1F ).
MCSF-R expression and α-SMA expression in profusely proliferated neointima are shown in Figure 1G and H. MCSF-R-positive cells were scattered in this stage ( Figure 1G) ; however, α-SMA was markedly expressed in the neointima ( Figure 1H ). Expression of growth factors in neointima: b-FGF and PDGF expression in neointima at various stages after stent implantation is shown in Figure 2 . In the early stage, stent struts were enveloped in thrombi (Figure 2A ) in which both growth factors were positively expressed ( Figure 2B, C) . At 45 days after stenting ( Figure 2D ), both growth factors were diffusely expressed in neointima that was composed mainly of VSMCs (Figure 2E, F) . At 150 days after stenting ( Figure  2G ), b-FGF-positive cells were still observed in the neointima, whereas PDGFpositive cells appeared to be decreased at this stage ( Figure 2H , I). Expression of cyclin D1 and cyclin-dependent kinase inhibitors: Expression of cyclin D1 and other cell cycle regulators in the early neointima 9 days, 40 days, and 111 days after stenting is shown in Figure 3 . PTAH stain was concentrated in early neointima primarily composed of thrombi that surrounded stent struts (Figure 3A) . Cyclin D1-positive cells were observed in early neointima ( Figure 3B ). p16-and p27-staining was also positive in early neointima ( Figure 3C, E) . p21positive cells were not observed in this patient ( Figure 3D ). On day 40 after stenting, neointima was composed mainly of VSMCs (Figure 3F) , with diffuse, strong cyclin D1 staining in the neointima ( Figure 3G ). Strong p16 expression was observed as well ( Figure 3H ), but p27 expression was decreased ( Figure 3J) . A small number of p21-positive cells were observed in the neointima ( Figure 3I ). Excessive proliferation of neointima was observed 111 days after stenting ( Figure 3K ). The expression of p16 remained positive ( Figure 3M ). Cyclin D1 expression was decreased in this stage; however, p27-positive cells were upregulated ( Figure 3L, O) . The expression of p21 was still minimal ( Figure 3N ). Quantitative analysis: The results of quantitative analysis of the percentage of positive immunostained cells in neointima are shown in Figure 4 . The percentage of α-SMA-positive cells increased 15 days after stenting, whereas the percentage of MCSF-R-positive cells was decreased 60 days after stenting ( Figure 4A ). b-FGF showed a continuously high percentage of positive cells in all stages. The percentage of PDGF-positive cells was increased 15 days after stenting and decreased 60 days after stenting ( Figure 4B ). Regarding the cell cycle regulators, the expression of cyclin D1-positive cells was downregulated 60 days after stenting. p27 expression of neointima was downregulated after 15 days but was upregulated 60 days after stenting. The percentage of p16 positive cells was continuously high and the percentage of p21 positive cells was minimal throughout all three stages ( Figure 4C ).
DISCUSSION
Regulation of VSMC proliferation is necessary for vascular proliferative response after vascular injury. In vascular injury caused by balloon angioplasty, laceration through the internal elastic lamina that extends from the intimal lesion into the media induces extensive VSMC proliferation, and thrombus formation and macrophage infiltration occur in the early stage of medial injury lesioning. 12) In the case of coronary stenting, the stent wire itself may also influence neointimal proliferation. 13) Pathological evaluation has shown that thrombus formation around stent struts is unique to the early stage after stenting. 2,3) Furthermore, excessive neointimal proliferation has been observed at sites free from medial damage. This phenomenon suggests that early thrombus around stent struts induces neointimal proliferation after stenting. However, the stent wire itself may promote neointimal formation through mechanical stretch or allergic reaction. 14) Chronic infiltration of inflammatory cells such as macrophages has been reported in the neointima around stent struts. 2, 3, 15) Certainly, both thrombus and inflammatory cells can contribute to neointimal formation by releasing cytokines and growth factors.
VSMCs in the neointima undergo changes that resemble dedifferentiation. Although they lose the capacity to contract by loss of α-actin, they gain the capacity to divide. MCSF-R is encoded by the c-fms proto-oncogene, 16) and MCSF-R expression has been reported on dedifferentiated SMCs and macrophages but not on normal medial SMCs. 17) In the present study, MCSF-R-positive cells were observed in the neointima from the early stage after stenting. Some of these cells were identified as macrophages, but others included dedifferentiated VSMCs. Migration of redifferentiated VSMCs was observed in the neointima from the early stage after stenting. However, some MCSF-R-positive cells exhibited positive expression of α-SMA. Recently, Sata, et al reported that some SMCs in an injured vessel are derived from hematopoietic stem cells. 18) MCSF-R and α-SMA double positive cells may indicate bone marrow-derived hematopoetic stem cells.
Dedifferentiation of VSMCs was stimulated by growth factors such as PDGF and b-FGF. In the small animal model of vascular injury, PDGF acts primarily to induce VSMC migration and secondarily to promote neointimal proliferation. 19) PDGF is commonly expressed in activated platelets, but other vascular cells such as macrophages, endothelial cells, and dedifferentiated SMCs can also express PDGF. 20) In the present study, PDGF expression was observed both in early thrombi and neointima. Furthermore, this expression was decreased in the chronic stage after stenting. This suggests that PDGF is strongly involved in the proliferation of VSMCs by inducing cell cycle regulators. In contrast, b-FGF expression was observed continuously. Conversely, b-FGF has been found to prevent apoptosis of VSMCs. 21) b-FGF may act mainly in the maintenance of VSMCs rather than in their proliferation after human coronary stenting.
Some experimental findings suggest that, among the CdkIs, p27 plays the most important role in suppression of VSMC proliferation after arterial injury. 22, 23) p27 appears to significantly inhibit intimal cell proliferation and neointimal development after vascular injury, whereas p16 expression does not appear to lead to a reduction in cell proliferation or neointima formation. 22) Histological investigation of the expression of cell cycle regulators after arterial injury has been performed previously in humans and other mammals. In stent restenosis in peripheral arteries, cyclin E and cdk2 were detected in proliferated VSMCs. 24) Tanner, et al demonstrated in a porcine balloon injury model that p27 expression was decreased 4 days after arterial injury but increased from day 14 through day 60, whereas p21 was undetectable when the response to injury was complete. 25) In the present study, we observed the expression of cyclin D1 to coincide with neointimal proliferation and to be downregulated in the late stage of neointimal proliferation. The expression of p27 appeared to be downregulated with neointimal proliferation and upregulated at the late stage in our limited number of cases. These results are compatible with those of other studies. 22, 23, 25) This suggests that, among the CdkIs, p27 plays the most important role in neointimal formation after coronary stenting in humans. Clinical implication: Restenosis continues to be an important problem after percutaneous coronary intervention. Intracoronary radiation is considered to be one of the most promising treatments for preventing restenosis after stenting. 26) Despite this, edge restenosis and late thrombosis have been reported as undesirable side effects. 27, 28) Recently, treatments that target cell cycle regulatory proteins as methods for preventing restenosis after coronary angioplasty have drawn attention. Sirolimus (rapamycin), an immunosuppressive agent, inhibits VSMC proliferation in vitro by blocking G1-S transition. 29) In an in vivo study of the porcine coronary balloon injury model, rapamycin significantly reduced the arterial proliferative response by increasing the level of p27. 30) More recently, Sousa, et al reported that sirolimus-coated stents reduced restenosis after angioplasty in humans. 31) In other experimental studies, a wide range of antiproliferative drugs have been shown to reduce neointimal proliferation after angioplasty by increasing p27 or p21 levels and decreasing cyclin D1 and E levels. 32, 33) The observations on human stenting we present strongly support these findings. Our results suggest, above all, that increasing p27 or decreasing cyclin D1 expression is one of the most promising approaches to preventing neointimal proliferation in humans after coronary stenting. Study limitations: This study is limited by the number of autopsied hearts implanted with coronary stents. Thus, these findings were obtained from hearts with various arteriosclerotic lesions, from plaques of varying stability such as lipid-rich or calcified plaques, and from various stent types, all of which may cause dissimilar neointimal proliferation. Moreover, the inflammatory reaction from stent implantation may differ from patient to patient.
